- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT00580112
An Efficacy Study of Trabectedin in the Treatment of Participants With Specific Subtypes of Metastatic Breast Cancer
24 februari 2014 uppdaterad av: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase II, Multicenter, Open-label, Clinical Trial of Trabectedin (Yondelis) in Metastatic Breast Cancer Patients With Triple Negative Profile (ER-, PR-, HER2-), HER2 Overexpressing Tumors and BRCA1 or BRCA2 Mutation Carriers
The purpose of this study is to evaluate the effectiveness and safety of trabectedin in 3 subpopulations of participants with previously treated progressive metastatic ( spread of a cancer from one organ or part to another non-adjacent organ or part) breast cancer (abnormal tissue that grows and spreads in the body until it kills) participants.
Studieöversikt
Status
Avslutad
Betingelser
Intervention / Behandling
Detaljerad beskrivning
This is an open-label (all people know the identity of the intervention), prospective (study following participants forward in time), multi-center (when more than 1 hospital or medical school team work on a medical research study) study evaluating the effectiveness and safety of trabectedin in 3 subpopulations of breast cancer participants: Group A: triple negative profile for estrogen receptor, progesterone receptor and human estrogen receptor, Group B: human epidermal growth factor receptor-2 overexpressing tumors (HER-2+) and Group C: familial breast cancer gene 1 (BRCA1) or breast cancer gene 2 (BRCA2) mutation carrier.
Participants will receive trabectedin 1.3 milligram per square meter (mg/m^2) intravenous infusion (a fluid or a medicine delivered into a vein by way of a needle) over 3-hour every 3 weeks, on Day 1 of each cycle.
Each cycle length will be 3 weeks.
Treatment will be continued until disease progression, unmanageable toxicity, participant refusal or treatment delay no longer than 3 weeks due to toxicity.
Efficacy will be primarily evaluated by percentage of participants with confirmed objective response by independent external review and Investigators assessment.
Participants' safety will be monitored throughout the study.
Studietyp
Interventionell
Inskrivning (Faktisk)
127
Fas
- Fas 2
Kontakter och platser
Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.
Studieorter
-
-
-
Bourdeaux, Frankrike
-
Marseille, Frankrike
-
Saint Herblain, Frankrike
-
Strasbourg Cedex, Frankrike
-
Villejuif, Frankrike
-
-
-
-
Arizona
-
Sedona, Arizona, Förenta staterna
-
-
Colorado
-
Denver, Colorado, Förenta staterna
-
-
Connecticut
-
Torrington, Connecticut, Förenta staterna
-
-
Indiana
-
Indianapolis, Indiana, Förenta staterna
-
-
Maryland
-
Westminster, Maryland, Förenta staterna
-
-
Minnesota
-
Minneapolis, Minnesota, Förenta staterna
-
-
Missouri
-
Columbia, Missouri, Förenta staterna
-
Kansas City, Missouri, Förenta staterna
-
St. Louis, Missouri, Förenta staterna
-
-
New York
-
Amsterdam, New York, Förenta staterna
-
New York, New York, Förenta staterna
-
-
Texas
-
Bedford, Texas, Förenta staterna
-
Dallas, Texas, Förenta staterna
-
Houston, Texas, Förenta staterna
-
San Antonio, Texas, Förenta staterna
-
Tyler, Texas, Förenta staterna
-
-
Virginia
-
Norfolk, Virginia, Förenta staterna
-
Salem, Virginia, Förenta staterna
-
-
Washington
-
Seattle, Washington, Förenta staterna
-
Spokane, Washington, Förenta staterna
-
Yakima, Washington, Förenta staterna
-
-
-
-
-
Jerusalem, Israel
-
Rehovot, Israel
-
Tel Hashomer, Israel
-
Tel-Aviv, Israel
-
-
-
-
-
Lubin, Polen
-
Rybnik, Polen
-
Szczecin, Polen
-
-
Deltagandekriterier
Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.
Urvalskriterier
Åldrar som är berättigade till studier
18 år och äldre (Vuxen, Äldre vuxen)
Tar emot friska volontärer
Nej
Kön som är behöriga för studier
Allt
Beskrivning
Inclusion Criteria:
- Participants with histologically proven diagnosis of progressive metastatic breast cancer
- Participants with measurable disease as per the Response Evaluation Criteria In Solid Tumors (RECIST) guidelines
- Participants with bone metastases currently receiving bisphosphonates for palliation will be eligible if other sites of measurable disease are present
- Participants with Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0 or 1 and adequately recovered from the acute toxicity of any prior treatment
- Participants with serum creatinine less than or equal to 1.5 milligram per deciliter (mg/dl) or creatinine clearance greater than or equal to 30 milliliter per minute (ml/min)
Exclusion Criteria:
- Participants with previous exposure to trabectedin
- Participants with more than 3 previous chemotherapy regimens for metastatic disease and known hypersensitivity to components of trabectedin intravenous formulation or dexamethasone
- Pregnant or lactating women or any women of childbearing potential who is not employing adequate contraception
- Completion of previous therapy : Less than 2 weeks from radiation therapy or last dose of hormonal therapy, less than 3 weeks from previous biological therapy or chemotherapy
- Participants with known leptomeningeal disease and other serious illnesses like congestive heart failure or angina pectoris; myocardial infarction within 1 year before enrolment; uncontrolled arterial hypertension or arrhythmias or active infection or psychiatric disorder or active viral hepatitis
Studieplan
Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Icke-randomiserad
- Interventionsmodell: Enskild gruppuppgift
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
---|---|
Experimentell: Group A
Participants with triple negative phenotype: estrogen receptor, progesterone receptor and human estrogen receptor-2 (HER-2) negative status for breast cancer (abnormal tissue that grows and spreads in the body until it kills) will receive trabectedin 1.3 milligram per meter square (mg/m^2) intravenous infusion (a fluid or a medicine delivered into a vein by way of a needle) over 3-hours (hrs) every 3 weeks, on Day 1 of each cycle.
Each cycle length will be 3 weeks.
Treatment will be continued until disease progression, unmanageable toxicity, participant refusal or treatment delay no longer than 3 weeks due to toxicity.
Along with study drug participants will be given dexamethasone 4 milligram (mg) orally 24 hrs and 12hrs before study drug infusion on Day -1, followed by dexamethasone 20 mg intravenously 30 minutes before study drug infusion on Day 1, followed by dexamethasone 4 mg orally 24, 36, 48, 60 and 72hrs after the start of study drug infusion from Day 1 to 3.
|
Dexamethasone 4 mg orally 24 hrs and 12 hrs before study drug infusion on Day -1, followed by dexamethasone 20 mg intravenously 30 minutes before study drug infusion on Day 1, followed by dexamethasone 4 mg orally 24, 36, 48, 60 and 72 hrs after the start of study drug infusion on Day 1 to 3.
Trabectedin 1.3 mg/m^2 intravenous infusion over 3-hrs every 3 weeks, on Day 1 of each cycle.
Each cycle length will be 3 weeks.
Andra namn:
|
Experimentell: Group B
Participants with overexpressing HER-2 breast cancer will receive trabectedin 1.3 mg/m^2 intravenous infusion over 3-hrs every 3 weeks, on Day 1 of each cycle.
Each cycle length will be 3 weeks.
Treatment will be continued until disease progression, unmanageable toxicity, participant refusal or treatment delay no longer than 3 weeks due to toxicity.
Along with study drug participants will be given dexamethasone 4 milligram (mg) orally 24 hrs and 12hrs before study drug infusion on Day -1, followed by dexamethasone 20 mg intravenously 30 minutes before study drug infusion on Day 1, followed by dexamethasone 4 mg orally 24, 36, 48, 60 and 72 hrs after the start of study drug infusion from Day 1 to 3.
|
Dexamethasone 4 mg orally 24 hrs and 12 hrs before study drug infusion on Day -1, followed by dexamethasone 20 mg intravenously 30 minutes before study drug infusion on Day 1, followed by dexamethasone 4 mg orally 24, 36, 48, 60 and 72 hrs after the start of study drug infusion on Day 1 to 3.
Trabectedin 1.3 mg/m^2 intravenous infusion over 3-hrs every 3 weeks, on Day 1 of each cycle.
Each cycle length will be 3 weeks.
Andra namn:
|
Experimentell: Group C
Participants with familial breast cancer gene 1 (BRCA1) or breast cancer gene 2 (BRCA2) mutation carriers cancer will receive trabectedin 1.3 mg/m^2 intravenous infusion over 3-hrs every 3 weeks on Day 1 of each cycle.
Each cycle length will be 3 weeks.
Treatment will be continued until disease progression, unmanageable toxicity, participant refusal or treatment delay no longer than 3 weeks due to toxicity.
Along with study drug participants will be given dexamethasone 4 mg orally 24 hrs and 12hrs before study drug infusion on Day -1, followed by dexamethasone 20 mg intravenously 30 minutes before study drug infusion on Day 1, followed by dexamethasone 4 mg orally 24, 36, 48, 60 and 72 hrs after the start of study drug infusion from Day 1 to 3.
|
Dexamethasone 4 mg orally 24 hrs and 12 hrs before study drug infusion on Day -1, followed by dexamethasone 20 mg intravenously 30 minutes before study drug infusion on Day 1, followed by dexamethasone 4 mg orally 24, 36, 48, 60 and 72 hrs after the start of study drug infusion on Day 1 to 3.
Trabectedin 1.3 mg/m^2 intravenous infusion over 3-hrs every 3 weeks, on Day 1 of each cycle.
Each cycle length will be 3 weeks.
Andra namn:
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Percentage of Participants With Confirmed Objective Response (OR) by Independent External Review (IER)
Tidsram: Baseline up to progressive disease or death, assessed every 6 weeks (up to 90 weeks)
|
Percentage of participants with confirmed objective response will be based on assessment of confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST).
Confirmed responses are those that persist on repeat imaging study at least 4 weeks after initial documentation of response.
CR is defined as disappearance of all target lesions.
PR is those with at least 30 percent decrease in the sum of longest dimensions of target lesions taking as a reference baseline sum longest dimensions.
IER will be done to re-examine all Investigator assessed outcomes.
|
Baseline up to progressive disease or death, assessed every 6 weeks (up to 90 weeks)
|
Percentage of Participants With Confirmed Objective Response (OR) by Investigators' Assessment
Tidsram: Baseline up to progressive disease or death, assessed every 6 weeks (up to 90 weeks)
|
Percentage of participants with objective response based assessment of confirmed CR or confirmed PR according to RECIST.
Confirmed responses are those that persist on repeat imaging study at least 4 weeks after initial documentation of response.
The CR is defined as disappearance of all target lesions.
The PR is those with at least 30 percent decrease in the sum of longest dimensions of target lesions taking as a reference baseline sum longest dimensions.
|
Baseline up to progressive disease or death, assessed every 6 weeks (up to 90 weeks)
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Duration of Response (DR) by Independent Expert Review (IER)
Tidsram: Baseline up to progressive disease or death, assessed every 6 weeks (up to 90 weeks)
|
Duration of Response is considered as time in months from the first documentation of objective tumor response to objective tumor progression or death due to any cause.
Duration of tumor response was calculated as: (the date of the first documentation of objective tumor progression or death due to cancer minus the date of the first CR or PR that will be subsequently confirmed plus 1) divided by 30.44.
DR will be calculated for the subgroup of participants with a confirmed objective tumor response.
IER will be done to re-examine all Investigator assessed outcomes and to provide an independent assessment of response and progression date.
|
Baseline up to progressive disease or death, assessed every 6 weeks (up to 90 weeks)
|
Duration of Response (DR) by Investigators' Assessment
Tidsram: Baseline up to progressive disease or death, assessed every 6 weeks (up to 90 weeks)
|
Duration of Response is considered as time in months from the first documentation of objective tumor response to objective tumor progression or death due to any cause.
Duration of tumor response is calculated as: (the date of the first documentation of objective tumor progression or death due to cancer minus the date of the first CR or PR that will be subsequently confirmed plus 1) divided by 30.44.
The DR will be calculated for the subgroup of participants with a confirmed objective tumor response.
|
Baseline up to progressive disease or death, assessed every 6 weeks (up to 90 weeks)
|
Progression-Free Survival (PFS) by Independent Expert Review (IER)
Tidsram: Baseline up to progressive disease or death, assessed every 6 weeks (up to 90 weeks)
|
PFS is defined as the time in months from start of study treatment to first documentation of objective tumor progression or death due to any cause whichever comes first.
PFS is calculated as (first event date minus the date of first dose of study medication plus 1) divided by 30.44.
Tumor progression will be determined from radiological image (where data meet the criteria for progressive disease [PD]).
IER will be done to re-examine all Investigator assessed outcomes and to provide an independent assessment of response and progression date.
|
Baseline up to progressive disease or death, assessed every 6 weeks (up to 90 weeks)
|
Progression-Free Survival (PFS) by Investigators' Assessment
Tidsram: Baseline up to progressive disease or death, assessed every 6 weeks (up to 90 weeks)
|
PFS is defined as the time in months from start of study treatment to first documentation of objective tumor progression or death due to any cause whichever comes first.
PFS is calculated as (first event date minus the date of first dose of study medication plus 1) divided by 30.44.
Tumor progression will be determined from radiological image (where data meet the criteria for progressive disease [PD]).
IER will be done to re-examine all Investigator assessed outcomes and to provide an independent assessment of response and progression date.
|
Baseline up to progressive disease or death, assessed every 6 weeks (up to 90 weeks)
|
Number of Participants With Changes in Tumor Volume
Tidsram: Baseline up to progressive disease or death, assessed every 6 weeks (up to 90 weeks)
|
Three dimensional analysis will be used to measure changes in tumor volume.
|
Baseline up to progressive disease or death, assessed every 6 weeks (up to 90 weeks)
|
Number of Participants With Changes in Tumoral Radiological Density
Tidsram: Baseline up to progressive disease or death, assessed every 6 weeks (up to 90 weeks)
|
Three dimensional analysis will be used to measure changes in tumoral radiological density.
|
Baseline up to progressive disease or death, assessed every 6 weeks (up to 90 weeks)
|
Andra resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Number of Participants With Adverse Events
Tidsram: Baseline up to 30 days after last dose of study drug
|
An adverse event is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product.
|
Baseline up to 30 days after last dose of study drug
|
Samarbetspartners och utredare
Det är här du hittar personer och organisationer som är involverade i denna studie.
Samarbetspartners
Publikationer och användbara länkar
Den som ansvarar för att lägga in information om studien tillhandahåller frivilligt dessa publikationer. Dessa kan handla om allt som har med studien att göra.
Studieavstämningsdatum
Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.
Studera stora datum
Studiestart
1 juni 2007
Primärt slutförande (Faktisk)
1 augusti 2011
Avslutad studie (Faktisk)
1 augusti 2011
Studieregistreringsdatum
Först inskickad
20 december 2007
Först inskickad som uppfyllde QC-kriterierna
20 december 2007
Första postat (Uppskatta)
24 december 2007
Uppdateringar av studier
Senaste uppdatering publicerad (Uppskatta)
25 februari 2014
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
24 februari 2014
Senast verifierad
1 februari 2014
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
- Hudsjukdomar
- Neoplasmer
- Neoplasmer efter plats
- Bröstsjukdomar
- Bröstneoplasmer
- Läkemedels fysiologiska effekter
- Molekylära mekanismer för farmakologisk verkan
- Autonoma agenter
- Agenter från det perifera nervsystemet
- Antiinflammatoriska medel
- Antineoplastiska medel
- Antiemetika
- Gastrointestinala medel
- Glukokortikoider
- Hormoner
- Hormoner, hormonsubstitut och hormonantagonister
- Antineoplastiska medel, hormonella
- Antineoplastiska medel, Alkylering
- Alkyleringsmedel
- Dexametason
- Trabectedin
Andra studie-ID-nummer
- CR014764
- ET-B-027-06 (Annan identifierare: Johnson & Johnson Pharmaceutical Research and Development, L.L.C.)
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Bröstneoplasmer
-
Tianjin Medical University Cancer Institute and...Guangxi Medical University; Sun Yat-sen University; Chinese PLA General Hospital och andra samarbetspartnersAvslutadDen kliniska tillämpningsguiden för Conebeam Breast CTKina
-
ETOP IBCSG Partners FoundationAvslutadBreast Cancer Invasive NosItalien
-
Spanish Breast Cancer Research GroupHoffmann-La Roche; Roche Farma, S.AAvslutadBreast Cancer Invasive NosSpanien
-
Pomeranian Medical University SzczecinMaria Sklodowska-Curie National Research Institute of Oncology; Regional...OkändBRCA1-mutation | Breast Cancer Invasive NosPolen
-
University Health Network, TorontoAvslutadBreast Cancer Invasive Nos | Primär invasiv bröstcancerKanada
-
Novartis PharmaceuticalsAvslutadMetastaserad bröstcancer (MBC) | Locally Advance Breast Cancer (LABC)Storbritannien, Spanien
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)AvslutadMetastatisk malign neoplasm | Ooperbar malign neoplasm | Avancerad malign neoplasmFörenta staterna
-
Massachusetts General HospitalRekryteringMalign neoplasm | Benign neoplasmFörenta staterna
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Aktiv, inte rekryterandeMetastatisk malign neoplasm | Avancerad malign neoplasm | Återkommande malign neoplasm | Refraktär malign neoplasm | Lokalt avancerad malign neoplasmFörenta staterna
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Aktiv, inte rekryterandeMalign neoplasm | Metastatisk malign neoplasm | Avancerad malign neoplasm | Återkommande malign neoplasm | Lokalt avancerad malign neoplasmFörenta staterna
Kliniska prövningar på Dexamethasone
-
Loyola UniversityMerck Sharp & Dohme LLCAvslutad
-
Ocular Therapeutix, Inc.AvslutadÖgoninflammation och smärtaFörenta staterna
-
Mercator MedSystems, Inc.AvslutadPerifera artärsjukdomarFörenta staterna
-
Oncopeptides ABPRA Health SciencesAvslutadAL AmyloidosSpanien, Storbritannien, Tyskland, Norge, Israel, Frankrike, Förenta staterna, Tjeckien, Grekland
-
University of Sao PauloDuke University; Fundação de Amparo à Pesquisa do Estado de São PauloAvslutadPostoperativ kognitiv dysfunktionBrasilien
-
Stony Brook UniversityRekryteringAlkoholmissbrukFörenta staterna
-
General Hospital Sveti DuhAvslutadLårbensfraktur | Kognitionsstörningar | Kortisol; HypersekretionKroatien